Medication Risk Mitigation : Coordinating and Collaborating with Health Care Systems, Universities, and Researchers to Facilitate the Design and Execution of Practice-Based Research - 14/12/17
, Calvin H. Knowlton, BPharm, MDiv, PhD, Jacques Turgeon, BPharm, PhDRésumé |
The high prevalence of inappropriate polypharmacy in geriatric populations is unacceptable. Traditional medication risk mitigation (MRM) strategies have proven to be effective at improving polypharmacy, but these strategies have not consistently translated into positive health outcomes. Enhanced MRM strategies, such as using pharmacogenomics information, are needed, and these strategies need to be tested. A formidable challenge is successfully integrating pharmacogenomic information into clinical practice. As the medication experts on health care teams, pharmacists have a clear role to play in developing, integrating, and assessing enhanced MRM strategies to improve therapeutic outcomes for geriatric patients.
Le texte complet de cet article est disponible en PDF.Keywords : Polypharmacy, Medication risk mitigation, Medication therapy management, Pharmacy practice, Personalized medicine, Pharmacogenomics
Plan
| Disclosure Statement: Tabula Rasa HealthCare, and the authors as stakeholders in Tabula Rasa HealthCare, have financial interests in the new multidrug analysis software the company has developed (Medication Risk Mitigation Matrix [Patent Pending]). This article, in parts or full, has not been submitted or presented elsewhere. |
Vol 33 - N° 2
P. 257-281 - mai 2017 Retour au numéro
Article précédent
- Can Managed Care Manage Polypharmacy?
- Richard G. Stefanacci, Taha Khan
- Geriatric Polypharmacy : Two Physicians' Personal Perspectives
- Zhe Chen, Anthony Buonanno
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?